The phase III KEYNOTE-716 trial investigating Keytruda, Merck’s anti-PD-1 therapy, met its primary endpoint of recurrence-free survival for the adjuvant treatment of patients with surgically resected high-risk stage II melanoma.
At an interim analysis, treatment with Keytruda as a single agent showed a statistically significant and clinically meaningful improvement in RFS compared with placebo as adjuvant therapy for these patients.
No new safety signals were observed. These results will be presented at an upcoming medical meeting.
Based on these data, FDA has accepted a new supplemental Biologics License Application for Keytruda for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.
The FDA granted the application Priority Review and assigned a Prescription Drug User Fee Act, or target action, date of Dec. 4, 2021.
